Literature DB >> 23112887

Durable, complete remission with bevacizumab-based chemotherapy in a patient with metastatic gastroesophageal junction cancer.

Mohammad H Rashid1, Mersiha Hadziahmetovic, Uzair B Chaudhary.   

Abstract

Entities:  

Year:  2012        PMID： 23112887      PMCID： PMC3481151     

Source DB:  PubMed          Journal:  Gastrointest Cancer Res        ISSN： 1934-7820


× No keyword cloud information.
  13 in total

1.  Prospective study of arterial infusion chemotherapy followed by radiofrequency ablation for the treatment of liver metastasis of gastric cancer.

Authors:  Koichiro Yamakado; Atsuhiro Nakatsuka; Haruyuki Takaki; Yasuhiro Mori; Hitoshi Tonouchi; Masato Kusunoki; Hideya Kida; Kan Takeda
Journal:  J Vasc Interv Radiol       Date:  2005-12       Impact factor: 3.464

2.  Long-term treatment with bevacizumab for patients with metastatic colorectal cancer: case report.

Authors:  Herbert I Hurwitz; Wanda Honeycutt; Sherri Haley; Justin Favaro
Journal:  Clin Colorectal Cancer       Date:  2006-05       Impact factor: 4.481

Review 3.  Antiangiogenic therapy for cancer: current and emerging concepts.

Authors:  Rakesh K Jain
Journal:  Oncology (Williston Park)       Date:  2005-04       Impact factor: 2.990

4.  First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study.

Authors:  Eduardo Díaz-Rubio; Auxiliadora Gómez-España; Bartomeu Massutí; Javier Sastre; Albert Abad; Manuel Valladares; Fernando Rivera; Maria J Safont; Purificación Martínez de Prado; Manuel Gallén; Encarnación González; Eugenio Marcuello; Manuel Benavides; Carlos Fernández-Martos; Ferrán Losa; Pilar Escudero; Antonio Arrivi; Andrés Cervantes; Rosario Dueñas; Amelia López-Ladrón; Adelaida Lacasta; Marta Llanos; Jose M Tabernero; Antonio Antón; Enrique Aranda
Journal:  Oncologist       Date:  2012-01-10

5.  CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study.

Authors:  Jaffer A Ajani; Jackie Baker; Peter W T Pisters; Linus Ho; Paul F Mansfield; Barry W Feig; Chusilp Charnsangavej
Journal:  Cancer       Date:  2002-02-01       Impact factor: 6.860

6.  Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer.

Authors:  Ronald M Bukowski; Fairooz F Kabbinavar; Robert A Figlin; Keith Flaherty; Sandy Srinivas; Ulka Vaishampayan; Harry A Drabkin; Janice Dutcher; Sarah Ryba; Qi Xia; Frank A Scappaticci; David McDermott
Journal:  J Clin Oncol       Date:  2007-09-17       Impact factor: 44.544

Review 7.  Genetic pathways of two types of gastric cancer.

Authors:  Eiichi Tahara
Journal:  IARC Sci Publ       Date:  2004

8.  Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group.

Authors:  K F Giordano; A Jatoi; P J Stella; N Foster; L K Tschetter; S R Alberts; S R Dakhil; J A Mailliard; P J Flynn; D A Nikcevich
Journal:  Ann Oncol       Date:  2006-02-23       Impact factor: 32.976

Review 9.  Current questions in the treatment of advanced colorectal cancer: the CAIRO studies of the Dutch Colorectal Cancer Group.

Authors:  Lieke Simkens; Jolien Tol; Miriam Koopman; Linda Mol; Ninja Antonini; Hans van Krieken; Cornelis Punt
Journal:  Clin Colorectal Cancer       Date:  2008-03       Impact factor: 4.481

Review 10.  Nature meets nurture: molecular genetics of gastric cancer.

Authors:  Anya N Milne; F Carneiro; C O'Morain; G J A Offerhaus
Journal:  Hum Genet       Date:  2009-08-06       Impact factor: 4.132
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.